Clinical Trials Logo
  1. Home
  2. IBS
  3. NCT02981888

Fecal Metabolome and the Intestinal Microbiota in Irritable Bowel Syndrome — IBS  

IBS Clinical Trial

Official title:
Fecal Bile Acids, Fecal Short Chain Fatty Acids and the Intestinal Microbiota in Patients With Irritable Bowel Syndrome and Control Volunteers

Clinical Trial Summary

The purpose of this study is to find out the relationship between the bile acids, fatty acids (fatty acids are part of the diet) and bacteria that are present in the intestines.

Clinical Trial Description

There is emerging evidence that alterations in bile acids and SCFA associated with IBS could be associated with changes in the gut microbiota. In addition to modulating levels of intraluminal organic acids, it has been hypothesized that gut microbiota may alter local immune responses, modulate visceral pain responses, and impair gut barrier function. Our overall goal is to investigate the relationship between fecal bile acids, SCFA and the gut microbiota in IBS. Results of this pilot study could reveal insights into the interplay of the gut microbiota and small molecule mediators of IBS to suggest targeted clinical strategies for improved diagnosis and management of this important syndrome. AIM 1: Test the hypothesis that fecal organic acids (SFCA and bile acids) and fecal microbiota play an important role in IBS. AIM 2: Test the hypothesis that there is association between colonic transit and fecal microbiota in IBS ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02981888
Study type Observational
Source Indiana University
Contact
Status Completed
Phase
Start date July 1, 2016
Completion date April 27, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT04677881 - Health Effects of Different Types of Bread N/A
Completed NCT02293343 - 24 Hrs Histamine Profile in Healthy Persons and Patients With Food Intolerance N/A
Completed NCT01717404 - Effects of Mexiletine on Colonic Transit in a Patient With Irritable Bowel Syndrome - Constipation (IBS-C) Phase 1
Withdrawn NCT02313207 - Confocal Laser Endomicroscopy in IBS Patients N/A
Completed NCT02937506 - Patient Satisfaction With Propofol for Out Patient Colonoscopy Phase 4
Terminated NCT05579444 - Systems Biology of Gastrointestinal and Related Diseases
Completed NCT02419963 - Analyzing IBS to Identify Biomarkers and Microbiome Signatures N/A
Recruiting NCT06389851 - Effects of Tomato Consumption on Steatosis, Intestinal Function and Glucose and Lipid Metabolism in Subjects With NAFLD N/A
Recruiting NCT05815602 - Ebastine Versus Mebeverine in IBS Patients Phase 3
Completed NCT03482765 - A Study of Probiotics in IBS Subjects N/A
Completed NCT03986476 - The Effect of Two Probiotic Products on the Intestinal Barrier Function in Patients With Irritable Bowel Syndrome N/A
Recruiting NCT06275906 - Influence of a Mediterranean Diet Combined With a Physical Activity Intervention, on NAFLD and Inflammation Parameters. N/A
Not yet recruiting NCT05737277 - Gabapral in Pediatric IBS N/A
Active, not recruiting NCT05718505 - Comparison of the Atmo Motility Gas Capsule System to the Reference Standard N/A
Recruiting NCT06072287 - The Living With a Long-Term Condition Study
Completed NCT04953728 - Optimization of Transcutaneous Electrical Acustimulation (TEA) Modalities for Treatment of IBS-C N/A
Completed NCT02681666 - Mindfulness-Based Eating in Patients With Irritable Bowel Syndrome N/A
Completed NCT01667627 - Probiotic in Irritable Bowel Syndrome (IBS) Patients With Diarrhea Phase 4
Recruiting NCT01779765 - The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome (IBS) Phase 4
Completed NCT02009618 - The Effects of Rifaximin Therapy in Irritable Bowel Syndrome N/A